Abstract
Apalutamide increased overall survival and delayed time to initiation of cytotoxic chemotherapy versus placebo in patients with nonmetastatic castration-resistant prostate cancer. Prior analyses had demonstrated clinically impactful improvement in metastasis-free survival, time to symptomatic progression, and second progression-free survival with apalutamide.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 150-158 |
| Number of pages | 9 |
| Journal | European Urology |
| Volume | 79 |
| Issue number | 1 |
| DOIs | |
| State | Published - Jan 2021 |
Keywords
- Apalutamide
- Nonmetastatic castration-resistant prostate cancer
- Overall survival
- Subsequent therapy
- Time to cytotoxic chemotherapy
ASJC Scopus subject areas
- Urology
Access to Document
Other files and links
Fingerprint Dive into the research topics of 'Apalutamide and Overall Survival in Prostate Cancer'. Together they form a unique fingerprint.
Cite this
- APA
- Standard
- Harvard
- Vancouver
- Author
- BIBTEX
- RIS
Apalutamide and Overall Survival in Prostate Cancer. / Smith, Matthew R.; Saad, Fred; Chowdhury, Simon; Oudard, Stéphane; Hadaschik, Boris A.; Graff, Julie N.; Olmos, David; Mainwaring, Paul N.; Lee, Ji Youl; Uemura, Hiroji; De Porre, Peter; Smith, Andressa A.; Brookman-May, Sabine D.; Li, Susan; Zhang, Ke; Rooney, Brendan; Lopez-Gitlitz, Angela; Small, Eric J.
In: European Urology, Vol. 79, No. 1, 01.2021, p. 150-158.Research output: Contribution to journal › Article › peer-review
}
TY - JOUR
T1 - Apalutamide and Overall Survival in Prostate Cancer
AU - Smith, Matthew R.
AU - Saad, Fred
AU - Chowdhury, Simon
AU - Oudard, Stéphane
AU - Hadaschik, Boris A.
AU - Graff, Julie N.
AU - Olmos, David
AU - Mainwaring, Paul N.
AU - Lee, Ji Youl
AU - Uemura, Hiroji
AU - De Porre, Peter
AU - Smith, Andressa A.
AU - Brookman-May, Sabine D.
AU - Li, Susan
AU - Zhang, Ke
AU - Rooney, Brendan
AU - Lopez-Gitlitz, Angela
AU - Small, Eric J.
N1 - Funding Information: Financial disclosures : Matthew R. Smith certifies that all conflicts of interest, including specific financial interests and relationships and affiliations relevant to the subject matter or materials discussed in the manuscript (eg, employment/affiliation, grants or funding, consultancies, honoraria, stock ownership or options, expert testimony, royalties, or patents filed, received, or pending), are the following: Eric J. Small has had advisory roles for Fortis and Janssen Oncology; has received compensation for travel from Janssen; holds stock and interest in Fortis and Harpoon Therapeutics; has received honoraria from Janssen; and has received research funding from Janssen and Merck Sharp & Dohme. Fred Saad has had advisory roles for Astellas Pharma, AstraZeneca/MedImmune, Bayer, Janssen Oncology, and Sanofi; has received honoraria from AbbVie, Amgen, Astellas Pharma, AstraZeneca, Bayer, Janssen Oncology, and Sanofi; and has received research funding grants provided to the institution from Astellas Pharma, AstraZeneca, Bayer, Bristol Myers Squibb, Janssen Oncology, Pfizer, and Sanofi. Simon Chowdhury has had advisory roles for Astellas Pharma, Bayer, Clovis Oncology, Janssen-Cilag, and Pfizer; has served on speakers’ bureau for Pfizer; has received honoraria from Clovis Oncology and Novartis; and has received research funding from Clovis Oncology and Sanofi/Aventis. Stéphane Oudard has had advisory roles for Astellas Pharma, Bayer, Bristol Myers Squibb, Eisai, Janssen, Merck Sharp & Dohme, Novartis, Pfizer, and Sanofi; has received compensation for travel from Bayer, Bristol Myers Squibb, Eisai, Merck Sharp & Dohme, Novartis, and Pfizer; has received honoraria from Astellas Pharma, Bayer, Bristol Myers Squibb, Eisai, Janssen, Merck Sharp & Dohme, Novartis, Pfizer, and Sanofi; and has received research funding from Ipsen and Sanofi. Boris A. Hadaschik has had advisory roles for ABX, Astellas, Bayer, Bristol Myers Squibb, Janssen R&D, Lightpoint Medical, Inc., and Pfizer; has received research funding from Astellas, Bristol Myers Squibb, German Cancer Aid, German Research Foundation, and Janssen R&D; and has received compensation for travel from Astellas, AstraZeneca, and Janssen R&D. Julie N. Graff has had an advisory role for Exelixis; has received compensation for travel from Bayer, Clovis Oncology, and Merck Sharp & Dohme; holds patents, royalties, and intellectual property with Oncoresponse: Exceptional Responders; has received honoraria from Astellas, Bayer, Janssen Oncology, and Medivation; and has received research funding from Bristol Myers Squibb, Janssen Oncology, Medivation, Merck Sharp & Dohme, and Sanofi. David Olmos has had advisory roles for AstraZeneca, Bayer, Clovis Oncology, Daiichi-Sankyo, Janssen, MSD, and Genentech/Roche; has received compensation for travel from Bayer, Ipsen, Janssen, and Genentech/Roche; has received honoraria from Bayer, Janssen, and Sanofi; and has received research funding from Astellas, AstraZeneca, Bayer, Genentech/Roche, Janssen, Pfizer, Medivation, MSD, Pfizer, and Tokai Pharmaceuticals. Paul N. Mainwaring has had an advisory role with Pfizer; has participated in speakers’ bureau with Astellas, Ipsen, Janssen Oncology, Medivation, Merck Sharp & Dohme, Novartis, Pfizer, and Roche/Genentech; has received compensation for travel from Astellas, Ipsen, Janssen Oncology, Medivation, Merck Sharp & Dohme, Novartis, Pfizer, and Roche/Genentech; holds stock and interests with Xing Technologies; has received honoraria from Astellas, Ipsen, Janssen Oncology, Medivation, Merck Sharp & Dohme, and Novartis, Pfizer, and Roche/Genentech; and has received research funding from Merck KGaA. Funding Information: Ji Youl Lee declares no conflicts of interest. Hiroji Uemura has had advisory roles for AstraZeneca, Bayer, Janssen, and Takeda; has received compensation for travel from Astellas, Bayer, and Janssen; has received honoraria from Astellas, AstraZeneca, Bayer, FRI-Toyama chem., Janssen, Kyowa-Kirin, Sanofi, and Takeda; and has received research funding from Bayer, Chugai Pharmaceuticals, FRI-Toyama chem., Sanofi, Taiho, and Takeda. Peter De Porre, Andressa A. Smith, Sabine D. Brookman May, Susan Li, Ke Zhang, Brendan Rooney, and Angela Lopez-Gitlitz are current or former employees of Janssen Research & Development and hold/held stock in Johnson & Johnson. Matthew R. Smith has had advisory roles for Amgen, Bayer, Janssen Oncology, Lilly, Novartis, and Pfizer; has received compensation for travel from Amgen, Bayer, Janssen, and Lilly; and has received research funding from Bayer, Gilead Sciences, and Janssen Oncology. Publisher Copyright: © 2020 The Authors
PY - 2021/1
Y1 - 2021/1
N2 - Apalutamide increased overall survival and delayed time to initiation of cytotoxic chemotherapy versus placebo in patients with nonmetastatic castration-resistant prostate cancer. Prior analyses had demonstrated clinically impactful improvement in metastasis-free survival, time to symptomatic progression, and second progression-free survival with apalutamide.
AB - Apalutamide increased overall survival and delayed time to initiation of cytotoxic chemotherapy versus placebo in patients with nonmetastatic castration-resistant prostate cancer. Prior analyses had demonstrated clinically impactful improvement in metastasis-free survival, time to symptomatic progression, and second progression-free survival with apalutamide.
KW - Apalutamide
KW - Nonmetastatic castration-resistant prostate cancer
KW - Overall survival
KW - Subsequent therapy
KW - Time to cytotoxic chemotherapy
UR - http://www.scopus.com/inward/record.url?scp=85090311385&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85090311385&partnerID=8YFLogxK
U2 - 10.1016/j.eururo.2020.08.011
DO - 10.1016/j.eururo.2020.08.011
M3 - Article
C2 - 32907777
AN - SCOPUS:85090311385
VL - 79
SP - 150
EP - 158
JO - European Urology
JF - European Urology
SN - 0302-2838
IS - 1
ER -